Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis

Huiying Wan, Haiping Jia, Tian Xia, Dingding Zhang, Huiying Wan, Haiping Jia, Tian Xia, Dingding Zhang

Abstract

Janus kinase (JAK) inhibitors have become promising treatments for atopic dermatitis (AD), however no study directly comparing JAK inhibitors with each other has been reported. We conducted this network meta-analysis to determine the comparative efficacy and safety of three common oral JAK inhibitors including abrocitinib, baricitinib, and upadacitinib for moderate-to-severe AD. We first identified eligible studies from published meta-analyzes, then we searched PubMed to obtain additional studies published between February and July 2021. Clinical efficacy and safety were evaluated as primary and secondary outcome, respectively. After extracting data and assessing methodological quality, we utilized ADDIS 1.4 software to conduct pair-wise and network meta-analyzes. Ten eligible studies were included in the final analysis. Pooled results that abrocitinib, baricitinib, and upadacitinib obtained higher investigator global assessment (IGA), eczema area, and severity index (EASI) response, however abrocitinib and upadacitinib caused more treatment-emergent adverse events (TEAEs) regardless of doses, compared with placebo. Network meta-analyzes revealed that upadacitinib 30 mg was superior to all regimens and upadacitinib 15 mg was better than remaining regimens except for abrocitinib 200 mg in terms of IGA and EASI response. Moreover, abrocitinib 200 mg was superior to abrocitinib 100 mg, baricitinib 1 mg, 2 mg, and 4 mg for clinical efficacy. However, upadacitinib 30 mg caused more TEAEs. Abrocitinib, baricitinib, and upadacitinib were consistently effective therapies in adult and adolescent patients with AD; however, upadacitinib 30 mg may be the optimal option in short-term studies. More efforts should be done to reduce the risk of TEAEs caused by upadacitinib 30 mg.

Keywords: Janus kinase inhibitor; abrocitinib; atopic dermatitis; baricitinib; network meta-analysis; upadacitinib.

Conflict of interest statement

The authors declare that they have no conflict of interest.

© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.

Figures

FIGURE 1
FIGURE 1
Flow chart of searching and selecting eligible studies
FIGURE 2
FIGURE 2
Pair‐wise meta‐analysis of IGA (A), EASI (B), and TEAEs (C). Gray dashed line indicates no statistical significance. Red square represents a point estimate, and black horizontal line represents 95% confidence interval.
FIGURE 3
FIGURE 3
Network meta‐analysis of IGA (A), EASI (B), and TEAEs (C). Gray dashed line indicates no statistical significance. Red square represents a point estimate, and black horizontal line represents 95% credible interval.

References

    1. Boguniewicz M, Fonacier L, Guttman‐Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10‐22.e12.
    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345‐360.
    1. DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. 2012;33(3):227‐234.
    1. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population‐based study. J Allergy Clin Immunol. 2013;132(5):1132‐1138.
    1. Lebwohl M. Psoriasis. Ann Intern Med. 2018;168(7):ITC49‐ITC64.
    1. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health‐related quality of life and productivity in adults in the United States: an analysis using the National Health and wellness survey. J Am Acad Dermatol. 2017;77(2):274‐279.e273.
    1. Ring J, Zink A, Arents BWM, et al. Atopic eczema: burden of disease and individual suffering ‐ results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33(7):1331‐1340.
    1. Nørreslet LB, Ebbehøj NE, Ellekilde Bonde JP, Thomsen SF, Agner T. The impact of atopic dermatitis on work life ‐ a systematic review. J Eur Acad Dermatol Venereol. 2018;32(1):23‐38.
    1. Eichenfield LF, DiBonaventura M, Xenakis J, et al. Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the United States: analysis of a retrospective claims database. Dermatol Ther. 2020;10(4):791‐806.
    1. Adamson AS. The economics burden of atopic dermatitis. Adv Exp Med Biol. 2017;1027:79‐92.
    1. Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990‐2017. Br J Dermatol. 2021;184(2):304‐309.
    1. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84‐92.
    1. Grey K, Maguiness S. Atopic dermatitis: update for pediatricians. Pediatr Ann. 2016;45(8):e280‐e286.
    1. Mohan GC, Lio PA. Comparison of dermatology and allergy guidelines for atopic dermatitis management. JAMA Dermatol. 2015;151(9):1009‐1013.
    1. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116‐132.
    1. Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int. 2017;66(2):230‐247.
    1. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045‐1060.
    1. Worm M, Francuzik W, Kraft M, Alexiou A. Modern therapies in atopic dermatitis: biologics and small molecule drugs. J Dtsch Dermatol Ges. 2020;18(10):1085‐1092.
    1. Damsky W, Peterson D, Ramseier J, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021;147(3):814‐826.
    1. Shreberk‐Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745‐753.e719.
    1. Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology. 2019;58(Suppl 1):i4‐i16.
    1. Honstein T, Werfel T. The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2020;20(4):386‐394.
    1. Arora CJ, Khattak FA, Yousafzai MT, Ibitoye BM, Shumack S. The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: a systematic review and meta‐analysis. Dermatol Ther. 2020;33(4):e13685.
    1. Miao M, Ma L. The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta‐analysis. J Dermatolog Treat. 2021;27:1‐9.
    1. Tsai HR, Lu JW, Chen LY, Chen TL. Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta‐analysis of clinical trials. J Pers Med. 2021;11(4):279.
    1. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical Research Ed). 2021;372:n160.
    1. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta‐analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777‐784.
    1. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration Available from .
    1. Sarri G, Patorno E, Yuan H, et al. Framework for the synthesis of non‐randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta‐analysis for healthcare decision making. BMJ Evid Based Med. 2022;27(2):109‐119.
    1. Meher BR, Mohanty RR, Padhy BM. Efficacy and safety of abrocitinib for the treatment of moderate‐to‐severe atopic dermatitis: a meta‐analysis of randomized clinical trials. J Dermatolog Treat. 2021;1‐24:1‐9.
    1. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
    1. Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical challenges in network meta‐analysis. Ann Intern Med. 2013;159(2):130‐137.
    1. Brooks S, Gelman A. General Methods for monitoring convergence of iterative simulations. J Comput Graphi Stat. 1998;7:434‐455.
    1. Burger DA, Schall R. A Bayesian nonlinear mixed‐effects regression model for the characterization of early bactericidal activity of tuberculosis drugs. J Biopharm Stat. 2015;25(6):1247‐1271.
    1. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta‐analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002;21(11):1539‐1558.
    1. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta‐analysis. Stat Med. 2010;29(7–8):932‐944.
    1. Albert I, Makowski D. Ranking crop species using mixed treatment comparisons. Res Synth Methods. 2019;10(3):343‐359.
    1. Palma Perez S, Delgado RM. Practical considerations on detection of publication bias. Gac Sanit. 2006;20(Suppl 3):10‐16.
    1. Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242‐255.
    1. Guttman‐Yassky E, Teixeira HD, Simpson EL, et al. Once‐daily upadacitinib versus placebo in adolescents and adults with moderate‐to‐severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double‐blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151‐2168.
    1. Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or Dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101‐1112.
    1. Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of Oral Janus kinase 1 inhibitor Abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371‐1379.
    1. Guttman‐Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16‐week results from a randomized, placebo‐controlled trial. J Allergy Clin Immunol. 2020;145(3):877‐884.
    1. Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre, randomized, vehicle‐controlled clinical study. Br J Dermatol. 2018;178(2):424‐432.
    1. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double‐blind, vehicle‐controlled study and an open‐label, long‐term extension study. J Am Acad Dermatol. 2020;82(4):823‐831.
    1. Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of Abrocitinib in patients with moderate‐to‐severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863‐873.
    1. Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate‐to‐severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE‐AD5). J Am Acad Dermatol. 2021;85(1):62‐70.
    1. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate‐to‐severe atopic dermatitis (JADE MONO‐1): a multicentre, double‐blind, randomised, placebo‐controlled, phase 3 trial. Lancet. 2020;396(10246):255‐266.
    1. Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160.
    1. Guttman‐Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate‐to‐severe atopic dermatitis: a phase 2 parallel, double‐blinded, randomized placebo‐controlled multiple‐dose study. J Am Acad Dermatol. 2019;80(4):913‐921.e919.
    1. Reich K, Kabashima K, Peris K, et al. Efficacy and safety of Baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333‐1343.
    1. Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(6):1575‐1583.
    1. Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis. J Eur Acad Dermatol Venereol. 2021;35:1797‐1810.
    1. Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132(6):1337‐1347.
    1. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91‐101.
    1. Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288‐294.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren